Ad26.ZIKV.001 Zika Vaccine Description
Ad26.ZIKV.001 Zika Vaccine candidate is a replication-incompetent human adenovirus serotype 26 (ad26) vector.
Ad26.ZIKV.001 Zika Vaccine Indication
Ad26.ZIKV.001 Zika Vaccine candidate is indicated to induce neutralizing antibodies to prevent Zika virus (ZIKV) infection.
ZIKV is transmitted via Aedes aegypti mosquitoes and may cause severe congenital disease after maternal-fetal transmission.
Ad26.ZIKV.001 Zika Vaccine Dosage
In the phase 1 clinical trial, researchers found that 2 doses of Ad26.ZIKV.001 was safe causing mild to moderate reactogenicity and induced persistent neutralizing antibody responses. The single-dose had lower peak antibodies but were durable after 1 year.
Ad26.ZIKV.001 Zika Vaccine News
February 16, 2021 - A phase 1 trial of the Ad26.ZIKV.001 Zika vaccine candidate revealed no safety concerns. The antibodies peaked 14 days after the second vaccine and remained high for at least one year.
Ad26.ZIKV.001 Zika Vaccine Clinical Trials
Clinical Trial NCT03356561: A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.ZIKV.001 in 100 Healthy Adult Volunteers - Last Update Posted on October 15, 2019